Comprehensive Characterization and In vitro Evaluation of a Novel POQCL Drug Delivery System

Aim: Formulation and evaluation of the POQCL drug delivery system. Background: One of the major barriers in the formulation of dosage forms is the poor solubility of the drug. BCS class IV drugs are having a problem with pharmacokinetics or reaching the site of action. Poor water-soluble drugs of BCS class IV obstruct drug bioavailability and decrease their pharmaceutical development. An attempt has been made in this work to deliver the BCS class IV drug into a novel carrier dosage form i.e., liposomes using a novel lipid. Objective: Formulation of the POQCL drug delivery system. Characterization by average particle size, surface morphological analysis, % drug entrapment, drug loading, in vitro study of drug release, and kinetic models of drug release of the prepared POQCL formulation. Methods: POQCL was prepared by emulsification-evaporation technique with some modifications and evaluation was done by average particle size, surface morphological analysis, drug entrapment percentage, drug loading, in vitro study of drug release, and kinetic models of drug release. Results: The average size of particle and surface morphology of prepared POQCL were found to be 76.89 nm and spherical in shape. The percentage yield was found to be 62.5% for the POQCL formulation. The percentages of drug entrapment efficiency and loading capacity were found to be 90% and 47.36% respectively. The drug in vitro release outcomes were 24.27% within the 2 hours and 75.18% within 12 hours and followed the zero-order drug release kinetic model for the POQCL formulation. Conclusion: In this research study, we found that pilu oil is a useful novel lipid source in the formulation of liposome drug delivery for the encapsulation of BCS class IV drugs. POQCL formulation showed optimum average particle size with enhanced entrapment efficiency and drug loading as well as a sustained release of drug was found. In the future, the prepared liposomes of pilu oil may be considered as the choice of drug delivery system for BCS class IV drugs. © 2023 Bentham Science Publishers.